Landos Biopharma is a technology company.
Landos Biopharma has raised $70.0M across 2 funding rounds.
Landos Biopharma has raised $70.0M in total across 2 funding rounds.
Landos Biopharma was a clinical-stage biopharmaceutical company developing first-in-class, oral small-molecule therapeutics targeting novel immunometabolic pathways for patients with autoimmune diseases, particularly inflammatory bowel diseases like ulcerative colitis (UC) and Crohn's disease (CD).[1][2][5] It served patients facing therapeutic gaps in current treatments by creating safer, more effective oral medicines, with a pipeline including NX-13 (NLRX1 agonist for UC/CD), Omilancor (LANCL2 agonist for UC/CD/eosinophilic esophagitis), and LABP-104 (PLXDC2 agonist for systemic lupus erythematosus/RA), powered by its proprietary AI-based LANCE platform.[2][5][6] The company, based in Blacksburg, Virginia, with 11-50 employees and NASDAQ ticker LABP, showed growth through clinical advancements like Phase 2 trials and $60M Series B financing, but was acquired by AbbVie in May 2024, integrating its lead asset NX-13 into AbbVie's immunology portfolio.[1][6][8]
Landos Biopharma was founded in January 2017 by Josep Bassaganya-Riera, Ph.D., a visionary leader with expertise in precision medicine and immunometabolism, who built the company from inception using the LANCE platform for AI-driven target discovery.[5][7] The idea emerged from understanding cell metabolic pathways' role in modulating inflammation, aiming to target interfaces of immunity and metabolism for autoimmune diseases where traditional therapies fall short.[5] Early traction included clearing four FDA INDs, raising $60M in Series B financing in 2020, and advancing multiple candidates to clinical stages by 2021, with Bassaganya-Riera stepping down as CEO in 2021 after establishing a pipeline of seven novel targets.[5][7][8]
Landos rode the wave of AI-driven drug discovery and precision immunology, targeting immunometabolism—a trend gaining traction as biologics face limitations in autoimmune diseases affecting millions.[5][7] Timing aligned with rising IBD prevalence and demand for oral alternatives to injectables, bolstered by market forces like AbbVie's aggressive immunology expansion.[6] By validating novel pathways like NLRX1, Landos influenced the ecosystem, contributing assets like NX-13 to majors like AbbVie, accelerating innovation in gut-selective therapies and highlighting biotech's shift toward computational platforms for faster, cheaper development.[2][5][6]
Post-acquisition by AbbVie in 2024, Landos' independent story ends, but NX-13 advances in Phase 2 for UC (NEXUS trial), potentially transforming IBD care with its unique mechanism amid trends like AI-biopharma convergence and immunology M&A.[6] Evolving AbbVie priorities in inflammation and repair could drive NX-13 toward Phase 3, shaping oral therapy standards. Landos exemplified how nimble biotechs bridge therapeutic gaps, fueling larger players' missions for breakthrough autoimmune treatments—echoing its founding goal of safer, effective care.[1][6]
Landos Biopharma has raised $70.0M in total across 2 funding rounds.
Landos Biopharma's investors include Perceptive Advisors.
Landos Biopharma has raised $70.0M across 2 funding rounds. Most recently, it raised $60.0M Series B in August 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2019 | $60.0M Series B | Perceptive Advisors | |
| Sep 1, 2017 | $10.0M Series A | Perceptive Advisors |